See more : Accelerate Acquisition Corp. (AAQC-UN) Income Statement Analysis – Financial Results
Complete financial analysis of BioNxt Solutions Inc. (XPHYF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of BioNxt Solutions Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Golden Metal Resources PLC (GMET.L) Income Statement Analysis – Financial Results
- Saha Pathana Inter-Holding Public Company Limited (SPI.BK) Income Statement Analysis – Financial Results
- PNB Housing Finance Limited (PNBHOUSING.BO) Income Statement Analysis – Financial Results
- Neo Energy Metals Plc (NEO.L) Income Statement Analysis – Financial Results
- TAAL Enterprises Limited (TAALENT.BO) Income Statement Analysis – Financial Results
BioNxt Solutions Inc. (XPHYF)
About BioNxt Solutions Inc.
BioNxt Solutions Inc. operates as a bioscience company in Germany, Switzerland, Austria, Israel, and Canada. It develops drug delivery methods, such as transdermal patches and oral dissolvable films designed for delivery of neurological medications; and psychedelic medicine to treat mental health-related medical conditions, including depression, anxiety, addiction, and trauma-related stress disorder. The company also develops point-of-care diagnostics comprising rapid diagnostics and biosensor screening tests for early detection and the potential for better treatment outcomes, and improved disease management; and COVID-19 PCR diagnostic kit, peri-implantitis oral biosensor, and H1N1 (swine flu) and H5N1 (avian flu) oral biosensors. In addition, it offers analytical testing and consulting services; and engages in the pathogen and oral health diagnostic and screening test, thin film drug formulation, and psychedelic pharmaceutical production and formulation businesses. The company was formerly known as XPhyto Therapeutics Corp. and changed its name to BioNxt Solutions Inc. in November 2022. BioNxt Solutions Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
XPhyto Therapeutics says it is rapidly advancing its mescaline program for psychedelic therapies
XPhyto Provides Progress Report on Mescaline Program for Psychedelic Therapies
XPhyto Therapeutics' partner Max Pharma to launch sale of Covid-ID Lab test in Germany from May 25
XPhyto advances its Rotigotine drug delivery system for Parkinson's skin patches to a pivotal human trial
XPhyto is advancing its Rotigotine drug delivery system for Parkinson's skin patches to a pivotal human trial
XPhyto Establishes Proof of Concept Station for Point-of-Care 25-minute COVID-19 PCR Test in Germany
XPhyto Therapeutics pursues market access in Israel for its rapid 25-minute Covid-ID Lab test
XPhyto Pursues Market Access in Israel for its COVID-19 PCR Rapid Test
XPhyto Therapeutics takes 'critical' step towards commercial sales of Covid-ID Lab test in Germany
XPhyto Signs German Distribution, Storage and Logistics Agreement for 25-Minute COVID-19 PCR Test
Source: https://incomestatements.info
Category: Stock Reports